Vilsin 20 mg | Generic Avatrombopag by Drug International

Description

Dr. Daria Kwaśniewska ESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid physician prescription is mandatory before any order is processed. Avatrombopag is not approved for dengue-related thrombocytopenia.

Is Vilsin 20 mg right for your situation?

Review these criteria with your doctor before enquiring

✔ You may be a candidate if

✓Chronic immune thrombocytopenia (ITP) with inadequate response to prior therapy
✓Thrombocytopenia in adults with chronic liver disease scheduled for a procedure
✓Need a WHO-GMP generic alternative to Doptelet® (Swedish Orphan Biovitrum)
✓Hold a valid physician prescription

✖ May NOT be suitable if

✗Thrombocytopenia from dengue or other non-approved causes
✗History of arterial or venous thromboembolism, especially in chronic liver disease
✗Pregnant, planning pregnancy, or breastfeeding
✗Scheduled procedure within less than 5 days of starting (requires specific pre-procedure timing)

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Vilsin 20 mg?

Vilsin 20 mg is a generic formulation of Avatrombopag — an oral thrombopoietin (TPO) receptor agonist — manufactured by Drug International Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 20 mg of avatrombopag, the same active molecule found in Doptelet® (Swedish Orphan Biovitrum), and is dispensed under the Named Patient Program for patients with ITP or chronic liver disease thrombocytopenia.

A key practical advantage of avatrombopag is that it can be taken with food and has no chelation interactions — no need to avoid dairy, antacids, or mineral supplements around dosing, unlike eltrombopag.

Generic name	Avatrombopag
Reference brand	Doptelet® (Swedish Orphan Biovitrum)
Manufacturer	Drug International Ltd.
Standard	WHO-GMP Certified
Drug class	Thrombopoietin (TPO) Receptor Agonist
Dosage form	Tablet — 20 mg
Pack size	28 tablets per pack
Route	Oral · once daily, with food
Prescription	Required — physician only

How Avatrombopag Works

Platelets are produced by bone marrow megakaryocytes regulated by thrombopoietin (TPO). In conditions like ITP and chronic liver disease, platelet production is impaired, leading to dangerously low counts and bleeding risk before procedures.

Avatrombopag binds to and activates the TPO receptor on megakaryocyte precursors, stimulating platelet production through the same pathway as the body’s natural hormone. Unlike eltrombopag, avatrombopag does not chelate with metal ions and can be taken with food. In the ADAPT-1 and ADAPT-2 Phase 3 trials for chronic liver disease, avatrombopag significantly increased platelets above 50,000/μL prior to procedures, substantially reducing the need for platelet transfusions compared to placebo.

What to Expect: First 30 Days

The dosing pattern differs significantly between the two approved indications — understanding which applies is essential.

Chronic ITP: Continuous once-daily dosing at 20 mg, adjusted between 20–40 mg based on platelet response. Most patients begin to see platelet increases within 1–2 weeks.
Chronic liver disease (pre-procedure): A short 5-day course, starting 10–13 days before the scheduled procedure. Dose is 60 mg daily if pre-treatment platelets are below 40,000/μL, or 40 mg daily if platelets are 40,000–50,000/μL.
Week 4 onwards (ITP): If platelet counts are stable, dose adjustments and monitoring frequency settle into a routine. Blood counts continue throughout treatment.

Side Effects

Avatrombopag is generally well tolerated, but blood clot risk — particularly in patients with chronic liver disease — requires monitoring.

Common · Usually Manageable

Headache
Fatigue
Nausea
Easy bruising (from underlying thrombocytopenia)
Upper respiratory infections
Joint pain

Serious · Report Immediately

Thrombotic events — DVT, PE, portal vein thrombosis
Excessive platelet response (thrombocytosis)
Severe abdominal pain (possible portal/splenic vein thrombosis)

⚠ Call your doctor immediately if you experience:

Sudden leg swelling, pain, or redness (possible DVT)
Breathlessness or chest pain (possible pulmonary embolism)
Severe or sudden abdominal pain (possible portal/splenic vein thrombosis)

How to Take Vilsin 20 mg

Dose depends on indication — Chronic ITP: 20 mg once daily (adjusted 20–40 mg by response) · Chronic liver disease pre-procedure: 60 mg or 40 mg once daily for 5 days (dose based on pre-treatment platelet count). Follow your physician’s exact prescription.

1
Take with food — avatrombopag absorption is not significantly affected by food, and no dairy/calcium separation is required.
2
Same time each day — consistency helps maintain stable drug levels.
3
Swallow tablets whole with water. Do not chew or crush.
4
If you miss a dose, take it as soon as you remember the same day. If a full day has passed, skip it and continue your normal schedule.
5
Storage: below 30°C, protected from moisture and light, out of reach of children.

Caregiver Guidance

♥
Watch for blood clot warning signs — leg swelling/pain, breathlessness, or sudden severe abdominal pain need immediate medical attention, especially in patients with chronic liver disease.
♥
For the liver disease indication, track the 5-day course carefully — this short regimen must be timed precisely relative to the procedure date. Mark the start and end dates clearly.
♥
Track platelet monitoring appointments — dose adjustments in the ITP setting are made based on platelet counts, so regular blood tests are essential for safe dosing.

If the Medicine Stops Working

If platelet counts fail to respond adequately, your physician will typically discontinue avatrombopag and consider alternative TPO receptor agonists (such as eltrombopag or romiplostim) or other ITP management strategies. For the chronic liver disease indication, the pre-procedure regimen is not designed for repeated long-term use — ongoing management of the underlying liver disease should be addressed with a hepatologist.

Frequently Asked Questions

How is Vilsin different from Avalet (also avatrombopag)?

Both Vilsin and Avalet contain avatrombopag 20 mg manufactured by Drug International Ltd. — they are the same product under two brand names from the same manufacturer. Availability and pricing may vary by region and order volume. Contact us to confirm which is currently in stock for your country.

How is Vilsin different from eltrombopag (Elbonix/Elopag)?

Both are oral TPO receptor agonists but they are different molecules. Avatrombopag (Vilsin) can be taken with food with no dietary restrictions, while eltrombopag must be taken fasting and kept separated from dairy, antacids, and mineral supplements by at least 4 hours due to chelation interactions. Avatrombopag also has a specific indication for chronic liver disease pre-procedure use that eltrombopag does not share.

Can Vilsin be used for dengue thrombocytopenia?

No. Avatrombopag is not approved for dengue-related thrombocytopenia. Its approved indications are chronic ITP and thrombocytopenia in adults with chronic liver disease scheduled for a procedure. Dengue-related platelet drops should be managed according to your treating physician’s specific protocol.

How long before a procedure should I start the liver disease dose?

The 5-day course should begin 10–13 days before the scheduled procedure, so that peak platelet response aligns with the procedure date. Starting too late or too early reduces effectiveness. Your physician will calculate the exact start date based on the procedure schedule.

What platelet count am I aiming for?

The platelet target depends on the indication and clinical situation. For the liver disease pre-procedure setting, the goal is typically to raise platelets above 50,000/μL before the procedure. For ITP, the target is generally the lowest platelet count that prevents clinically significant bleeding — not necessarily a “normal” count. Your physician will set the target based on your specific situation.

How do I order Vilsin through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your physician’s prescription specifying your diagnosis and prescribed dose. Our team will verify the prescription, confirm availability and pricing, and arrange secure international shipping under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.

This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.

Clinical References

Terrault N, et al. Avatrombopag before procedures in patients with chronic liver disease and thrombocytopenia (ADAPT-1 and ADAPT-2). Lancet 2018;391:2163–2173.
Jurczak W, et al. Avatrombopag in the treatment of ITP. Eur J Haematol 2018;101:415–422.
FDA Prescribing Information: Doptelet (avatrombopag). Swedish Orphan Biovitrum, 2022.